Active Biotech AB Year-end report January - December 2012
(Thomson Reuters ONE) -
Events for the full year 2012
Laquinimod
* Phase III data presented at the AAN (64th Annual Meeting of the American
Academy of Neurology)
* Application submitted for regulatory approval in the EU, milestone payment
of USD 5 M from Teva
* Teva initiates a Phase III study in multiple sclerosis (the CONCERTO study)
in the US
* Positive Crohn's Phase II data presented at the UEGW conference
* Teva expands the clinical development program to encompass new indications
TASQ
* EUR 10 M milestone payment from Ipsen upon 600 patients enrolled in Phase
III study
* overall survival data from Phase II study presented
* biomarker data presented at the ESMO conference
* Ipsen initiated two new Phase II trials; a "switch maintenance" in prostate
cancer and
a second study into additional cancer forms
* Phase III study fully enrolled (1,245 patients); milestone payment of EUR
10 M from Ipsen
ANYARA
* Phase II/III study in renal cell cancer concluded
* Results presented during Q1, 2013:
- study did not achieve primary clinical endpoint
- doubling of progression free survival and OS in 25 % of patients
- planning of the continued clinical development ongoing
57-57
* clinical trial of systemic sclerosis/scleroderma concluded
ISI
* focus on patent submissions H1 2013
* project proceeds as planned
Oct - Dec Jan - Dec
(MSEK) 2012 2011 2012 2011
----------------------------------------------------------------------------
* Net sales 91.5 3.3 227.9 234.6
* Operating profit/loss 5.5 -94.7 -163.2 -100.9
* Net profit/loss 0.1 -93.2 -175.0 -94.5
* Profit/loss per share (SEK)
0.00 -1.35 -2.54 -1.38
For further information, please contact:
Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95
Hans Kolam, CFO Tel: +46 (0)46 19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00, Fax +46 (0)46 19 11 00
This report is also available at www.activebiotech.com
Active Biotech AB Year-end report Jan-Dec 2012:
http://hugin.info/1002/R/1678129/547591.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1678129]
Unternehmensinformation / Kurzprofil:
Datum: 14.02.2013 - 08:31 Uhr
Sprache: Deutsch
News-ID 229481
Anzahl Zeichen: 3305
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 144 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech AB Year-end report January - December 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
